You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

Article metrics

Article menu

Download PDFPDF

Lupus
Original research
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

 

Online download statistics by month:

Online download statistics by month: October 2022 to August 2024

AbstractFullPdf
Oct 202226426497
Nov 2022763754231
Dec 2022195374195375581
Jan 202333813374143
Feb 202320602057119
Mar 202323242319126
Apr 202314711466113
May 202312451238140
Jun 20232027201997
Jul 20232183217387
Aug 202322792257114
Sep 202318801863104
Oct 202315811572130
Nov 2023820803101
Dec 2023629595157
Jan 2024528484114
Feb 2024426411111
Mar 2024377366197
Apr 2024354333153
May 2024274248115
Jun 202431029498
Jul 2024320290102
Aug 2024292274112
Total2211622208293342